Commentary

The U.S. Obesity Epidemic and Surging Liver Cancer


 

If there is one truism that trumps everything else these days about U.S. health, it’s that America is a chubby country that keeps getting fatter.

The consequences seep into every corner of the nation’s medical state, including the surprising fact that obesity and the type 2 diabetes it causes are likely pushing up the incidence of liver cancer – hepatocellular carcinoma – to unprecedented heights.

Courtesy of Wikimedia Commons

When I covered Digestive Disease Week in San Diego recently, one of the biggest stories I heard was that U.S. liver-cancer rates tripled from 1975-2007, and that the numbers continued to rise from the mid to the late 2000s. (My full report on this is here).

Granted, factors other than just obesity play into the liver cancer surge, notably the sizable number of Americans infected with either hepatitis B or C virus, and the fact that as they age their risk for developing hepatocellular carcinoma rises.

But new U.S. infections by hepatitis B and C are largely under control these days (although people infected elsewhere continue to emigrate to the United States). The part of the booming liver-cancer story that is by no means under control is the obesity part.

Courtesy of the CDC

Every time I see a new CDC map for U.S. obesity prevalence, the colors on it keep getting redder and darker (the CDC’s code for higher prevalence rates).

Earlier this year, the CDC reported a 36% obesity prevalence rate for the entire U.S. population – and still on the rise – and just a few weeks ago we heard that obesity among children and adolescents had hit a new high of 17%. With obesity seemingly on an unchanging upward trajectory, one can only wonder what rates of liver cancer it might produce in the future. Obesity carries a special relationship with the liver, and it’s not pretty. Just consider any goose headed to a foie-gras future.

Courtesy of the CDC

Until now, the evidence linking obesity and liver cancer, and type 2 diabetes and liver cancer has been epidemiologic. Compelling, but just an association. At DDW, a new study provided more observational data on the diabetes-liver cancer link, and while still circumstantial it further supports the notion and also carries an intriguing punchline.

The study, done in Taiwan, examined 97,000 hepatocellular carcinoma patients and 195,000 matched controls. The analysis showed that people with diabetes had a two-fold increased risk for liver cancer compared with those without diabetes. Even more striking, the analysis also showed that people with diabetes treated with the oral hypoglycemic drug metformin had their risk for liver cancer cut in half compared with those not on metformin, and those with diabetes treated with a glitazone drug (such as pioglitazone-Actos) had their risk cut nearly in half.

The best solution would be if people avoided obesity and type 2 diabetes all together. Both conditions cause a lot of medical problems, and this new evidence indicates more strongly than ever before that liver cancer is one of them.

— Mitchel Zoler (on Twitter @mitchelzoler)

Recommended Reading

Physician-Led PACs Rise in Number, Influence
MDedge Hematology and Oncology
Chemoradiotherapy Improves Esophageal Cancer Outcomes
MDedge Hematology and Oncology
Liver Cancer Rates Continue to Rise, Vigilance Warranted
MDedge Hematology and Oncology
Vismodegib Proves Promising for Operable BCCs
MDedge Hematology and Oncology
Community Oncology Podcast - Erwinia asparaginase for acute lymphoblastic leukemia
MDedge Hematology and Oncology
Ruxolitinib treatment for myelofibrosis
MDedge Hematology and Oncology
Cancer recurrence and survival in patients with early-stage triple-negative breast cancer
MDedge Hematology and Oncology
Medullary thyroid cancer: advances in treatment and management of common adverse events associated with therapy
MDedge Hematology and Oncology
Biosimilars and their use in hematology and oncology
MDedge Hematology and Oncology
The Patient Protection and Affordable Care Act: no rhetoric, just the facts
MDedge Hematology and Oncology